BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34628548)

  • 1. Therapeutic efficacy of selective intra-arterial chemoradiotherapy with docetaxel and nedaplatin for fixed bulky nodal disease in head and neck cancer of unknown primary.
    Heianna J; Makino W; Hirakawa H; Agena S; Tomita H; Ariga T; Ishikawa K; Takehara S; Maemoto H; Murayama S
    Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):3105-3113. PubMed ID: 34628548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of selective intraarterial chemoradiotherapy with docetaxel and nedaplatin for human papilloma virus-negative oropharyngeal cancer.
    Heianna J; Makino W; Hirakawa H; Agena S; Tomita H; Ariga T; Ishikawa K; Takehara S; Kusada T; Maemoto H; Maeda H; Murayama S
    Auris Nasus Larynx; 2022 Jun; 49(3):468-476. PubMed ID: 34763986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of intra-arterial docetaxel and nedaplatin infusion concomitant with radiotherapy for T4 maxillary sinus squamous cell carcinoma.
    Heianna J; Makino W; Hirakawa H; Yamashita Y; Tomita H; Murayama S
    Int J Oral Maxillofac Surg; 2022 Sep; 51(9):1123-1130. PubMed ID: 34955352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of patients with head-and-neck cancer of unknown primary origin treated with intensity-modulated radiotherapy.
    Shoushtari A; Saylor D; Kerr KL; Sheng K; Thomas C; Jameson M; Reibel J; Shonka D; Levine P; Read P
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e83-91. PubMed ID: 21377283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of postoperative bio-chemoradiotherapy using cetuximab and docetaxel for high-risk head and neck cancer patients in Japan.
    Nishimura G; Shiono O; Sano D; Yabuki K; Arai Y; Chiba Y; Tanabe T; Oridate N
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):203-207. PubMed ID: 28597041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck squamous cell carcinoma.
    Okuda H; Ohnishi M; Takahashi H; Takagi C; Takada N; Ohashi T
    Auris Nasus Larynx; 2019 Dec; 46(6):882-888. PubMed ID: 31176493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organ preservation with daily concurrent chemoradiotherapy using superselective intra-arterial infusion via a superficial temporal artery for T3 and T4 head and neck cancer.
    Mitsudo K; Shigetomi T; Fujimoto Y; Nishiguchi H; Yamamoto N; Furue H; Ueda M; Itoh Y; Fuwa N; Tohnai I
    Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1428-35. PubMed ID: 20605340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.
    Harari PM; Harris J; Kies MS; Myers JN; Jordan RC; Gillison ML; Foote RL; Machtay M; Rotman M; Khuntia D; Straube W; Zhang Q; Ang K
    J Clin Oncol; 2014 Aug; 32(23):2486-95. PubMed ID: 25002723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Observance and results of concurrent chemoradiotherapy after induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil for locally advanced head and neck cancers].
    Calderon B; Guerder C; Resbeut M; Fakhry N; Dupuis C; Cowen D
    Cancer Radiother; 2016 Apr; 20(2):83-90. PubMed ID: 26969244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adjuvant chemotherapy (nedaplatin/UFT) after concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma].
    Kubota A; Furukawa M; Komatsu M; Hanamura H; Sugiyama M
    Nihon Jibiinkoka Gakkai Kaiho; 2006 Mar; 109(3):149-56. PubMed ID: 16615429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
    Komatsu M; Shiono O; Taguchi T; Sakuma Y; Nishimura G; Sano D; Sakuma N; Yabuki K; Arai Y; Takahashi M; Isitoya J; Oridate N
    Jpn J Clin Oncol; 2014 May; 44(5):416-21. PubMed ID: 24688084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
    J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HPV status in unknown primary head and neck cancer: Prognosis and treatment outcomes.
    Cheraghlou S; Torabi SJ; Husain ZA; Otremba MD; Osborn HA; Mehra S; Yarbrough WG; Burtness BA; Judson BL
    Laryngoscope; 2019 Mar; 129(3):684-691. PubMed ID: 30151832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
    Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superselective intra-arterial chemoradiotherapy with docetaxel-nedaplatin for advanced oral cancer.
    Kobayashi W; Teh BG; Sakaki H; Sato H; Kimura H; Kakehata S; Nagahata M
    Oral Oncol; 2010 Dec; 46(12):860-3. PubMed ID: 21050802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
    Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
    Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
    Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional control after concomitant chemoradiotherapy without planned neck dissection in node-positive head and neck squamous cell carcinomas.
    Sakashita T; Homma A; Oridate N; Suzuki S; Hatakeyama H; Kano S; Mizumachi T; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
    Auris Nasus Larynx; 2013 Apr; 40(2):211-5. PubMed ID: 22867524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.